east cancer, will be patentable. (Pollack, 6/69) Celeras stock currently has a 52-week low of 20- and 52-week high of 276. It had a 2 for 1 spit on February 22, 2000 before the split the stock price was 315.8125 per share. Currently it is a round 62- pre share . If all goes well with the U.S. Patent and Trademark Office share price should be going up in the near future. Human Genome Science Human Genome Science believes that it has mapped the genes responsible for producing proteins in the body. They also believe that their, genomics-based drugs will usher in a new generation of healthcare products. Which will spell profits for this company. Human Genomes stock has a 52-week high/low of 116.37 - 21.25. It has two 2 for 1 stock splits, the first occurred on January 31, 2000, before the market opened. Before the split the stock was priced at 191.125. The second stock split occurred on October 2, 2000, this price before splitting was 165. Currently the stock is priced around 74-. And on November 14, 2000, Prudential upgraded GHSI from accumulate to a strong buy. AmgenAmgen is a global biotechnology company that develops and manufactures human therapeutics. The products they produce are based on molecular and cellular biology. Amgens stock has been performing well, the 52-week low/high being, 42-5/8 80-7/16, respectively. With a price/earnings ratio of 60.16 and earning per share of 1.12 the stock is a strong buy. The stock has split 5 times since August 13, 1990, there were 4, 2 for 1s and one 3 for 1 splits. In the newsThere are hardly any profits and the price per share is high, this is a similar situation when compared to the internet stocks. But the payoff isnt in the near future, We will be sorting through the genome for literally decades, says Craig Venter, president of Celera Genomics. Jonas Alsenas, a portfolio manager says, The vast majority of new biotech companies dont have anything new and wont survive. There is a lot of ...
